Toward an effective targeted chemotherapy for multiple myeloma

Clin Cancer Res. 2009 Jun 15;15(12):3906-7. doi: 10.1158/1078-0432.CCR-09-0572. Epub 2009 Jun 9.

Abstract

Antibody-drug conjugates (ADCs), cytotoxic drugs chemically linked to antibodies, provide a means to increase the effectiveness of chemotherapy by targeting the drug to neoplastic cells. Anti-CD138 ADCs show promising preclinical efficacy for the treatment of multiple myeloma; however, the safety aspects of targeting CD138 have yet to be explored.

Publication types

  • Comment

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents / toxicity
  • Disease Models, Animal
  • Immunotoxins / immunology
  • Immunotoxins / therapeutic use*
  • Mice
  • Mice, SCID
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / immunology
  • Syndecan-1 / antagonists & inhibitors*
  • Syndecan-1 / immunology
  • Xenograft Model Antitumor Assays

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Immunotoxins
  • Syndecan-1